LNCaP公司
前列腺癌
体内分布
化学
药效团
尿素
体内
正电子发射断层摄影术
谷氨酸羧肽酶Ⅱ
前列腺
显像剂
癌症
体外
癌症研究
核医学
生物化学
医学
内科学
生物
生物技术
作者
Kelly Lu,Chengcheng Zhang,Zhengxing Zhang,Hsiou‐Ting Kuo,Nadine Colpo,François Bénard,Kuo‐Shyan Lin
出处
期刊:Molecules
[Multidisciplinary Digital Publishing Institute]
日期:2023-06-29
卷期号:28 (13): 5120-5120
被引量:8
标识
DOI:10.3390/molecules28135120
摘要
Prostate-specific membrane antigen (PSMA) is a well-validated prostate cancer marker but reported PSMA-targeted tracers derived from the Lys-urea-Glu pharmacophore including the clinically validated [99mTc]Tc-EDDA/HYNIC-iPSMA have high off-target uptake in kidneys, spleen, and salivary glands. In this study, we synthesized and evaluated three novel 99mTc-labeled PSMA-targeted tracers and investigated if the tracers derived from the Lys-urea-Aad pharmacophore could have minimized uptake in off-target organs/tissues. In vitro competition binding assays showed that compared with HYNIC-iPSMA, the three novel ligands had slightly weaker PSMA binding affinity (average Ki = 3.11 vs. 8.96–11.6 nM). Imaging and ex vivo biodistribution studies in LNCaP tumor-bearing mice showed that [99mTc]Tc-EDDA/HYNIC-iPSMA and the three novel tracers successfully visualized LNCaP tumor xenografts in SPECT images and were excreted mainly via the renal pathway. The average tumor uptake at 1 h post-injection varied from 5.40 to 18.8%ID/g, and the tracers derived from the Lys-urea-Aad pharmacophore had much lower uptake in the spleen and salivary glands. Compared with the clinical tracer [99mTc]Tc-EDDA/HYNIC-iPSMA, the Lys-urea-Aad-derived [99mTc]Tc-EDDA-KL01127 had lower background uptake and superior tumor-to-background contrast ratios and is therefore promising for clinical translation to detect prostate cancer lesions with SPECT.
科研通智能强力驱动
Strongly Powered by AbleSci AI